186 related articles for article (PubMed ID: 35672651)
1. Exploring chitosan-shelled nanobubbles to improve HER2 + immunotherapy via dendritic cell targeting.
Argenziano M; Occhipinti S; Scomparin A; Angelini C; Novelli F; Soster M; Giovarelli M; Cavalli R
Drug Deliv Transl Res; 2022 Aug; 12(8):2007-2018. PubMed ID: 35672651
[TBL] [Abstract][Full Text] [Related]
2. Application of microneedles combined with dendritic cell-targeted nanovaccine delivery system in percutaneous immunotherapy for triple-negative breast cancer.
Weng J; Yang J; Wang W; Wen J; Fang M; Zheng G; Xie J; Zheng X; Feng L; Yan Q
Nanotechnology; 2023 Sep; 34(47):. PubMed ID: 37478829
[TBL] [Abstract][Full Text] [Related]
3. Immunotheranostic microbubbles (iMBs) - a modular platform for dendritic cell vaccine delivery applied to breast cancer immunotherapy.
Jugniot N; Dahl JJ; Paulmurugan R
J Exp Clin Cancer Res; 2022 Oct; 41(1):299. PubMed ID: 36224614
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
[TBL] [Abstract][Full Text] [Related]
5. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
6. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
[TBL] [Abstract][Full Text] [Related]
7. miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy.
Zhang M; Shi Y; Zhang Y; Wang Y; Alotaibi F; Qiu L; Wang H; Peng S; Liu Y; Li Q; Gao D; Wang Z; Yuan K; Dou FF; Koropatnick J; Xiong J; Min W
Cancer Immunol Immunother; 2020 Jun; 69(6):951-967. PubMed ID: 32076794
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.
Bryson PD; Han X; Truong N; Wang P
Vaccine; 2017 Oct; 35(43):5842-5849. PubMed ID: 28916248
[TBL] [Abstract][Full Text] [Related]
10. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice.
Jadidi-Niaragh F; Atyabi F; Rastegari A; Kheshtchin N; Arab S; Hassannia H; Ajami M; Mirsanei Z; Habibi S; Masoumi F; Noorbakhsh F; Shokri F; Hadjati J
J Control Release; 2017 Jan; 246():46-59. PubMed ID: 27993599
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
Klippstein R; Pozo D
Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
[TBL] [Abstract][Full Text] [Related]
12. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy.
Han HD; Byeon Y; Jang JH; Jeon HN; Kim GH; Kim MG; Pack CG; Kang TH; Jung ID; Lim YT; Lee YJ; Lee JW; Shin BC; Ahn HJ; Sood AK; Park YM
Sci Rep; 2016 Dec; 6():38348. PubMed ID: 27910914
[TBL] [Abstract][Full Text] [Related]
13. DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice.
Cao J; Jin Y; Li W; Zhang B; He Y; Liu H; Xia N; Wei H; Yan J
BMC Immunol; 2013 Aug; 14():39. PubMed ID: 23941509
[TBL] [Abstract][Full Text] [Related]
14. HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.
Zizzari IG; Veglia F; Taurino F; Rahimi H; Quaglino E; Belleudi F; Riccardo F; Antonilli M; Napoletano C; Bellati F; Benedetti-Panici P; Torrisi MR; Frati L; Nuti M; Rughetti A
J Mol Med (Berl); 2011 Dec; 89(12):1231-40. PubMed ID: 21845448
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells.
Le Moignic A; Malard V; Benvegnu T; Lemiègre L; Berchel M; Jaffrès PA; Baillou C; Delost M; Macedo R; Rochefort J; Lescaille G; Pichon C; Lemoine FM; Midoux P; Mateo V
J Control Release; 2018 May; 278():110-121. PubMed ID: 29630987
[TBL] [Abstract][Full Text] [Related]
17. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
[TBL] [Abstract][Full Text] [Related]
18. Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine.
Esmaily M; Masjedi A; Hallaj S; Nabi Afjadi M; Malakotikhah F; Ghani S; Ahmadi A; Sojoodi M; Hassannia H; Atyabi F; Namdar A; Azizi G; Ghalamfarsa G; Jadidi-Niaragh F
J Control Release; 2020 Oct; 326():63-74. PubMed ID: 32580042
[TBL] [Abstract][Full Text] [Related]
19. Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine.
Jahan ST; Sadat SM; Haddadi A
Int J Nanomedicine; 2018; 13():367-386. PubMed ID: 29391795
[TBL] [Abstract][Full Text] [Related]
20. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
